Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches

doi:10.12114/j.issn.1007-9572.2025.0317

Abstract

Abstract:

Hyperlipidemia can be complicated by various cardiovascular and metabolic diseases, posing an increasingly serious threat to human health. Clinically, blood lipid levels are often defined based on fasting blood levels in the early morning. However, in the real world, the human body is not in a fasting state for most of the time, and simply detecting fasting blood lipid levels is difficult to reflect the full picture of lipid metabolism in the body. In recent years, multiple studies at home and abroad have focused on postprandial hyperlipidemia, exploring various aspects such as its diagnosis and treatment. This article reviews the latest research on the evaluation methods, inducing factors, complications, and treatment approaches of postprandial hyperlipidemia, aiming to provide reference and assistance for the clinical diagnosis and treatment of postprandial hyperlipidemia.

Key words: Hyperlipidemias, Postprandial hyperlipidemia, Oral fat tolerance test, Triglyceride, Postprandial hyperglycaemia, Atherosclerosis

摘要：

高脂血症可并发诸多心血管及代谢疾病，对人类健康威胁日益严重。临床上常以清晨空腹血脂水平来定义血脂水平，但真实世界中人体绝大部分时间并非处于空腹状态，单纯检测空腹血脂水平难以反映体内脂代谢的全貌。近年来国内外多项研究以餐后高脂血症为核心，探讨了关于其诊断及治疗等多个方面。本文对餐后高脂血症的评价方法、诱因、并发症及治疗方法的最新研究进行了综述，以期对临床上餐后高脂血症的诊断及治疗提供参考和帮助。

关键词: 高脂血症, 餐后高脂血症, 口服脂肪负荷试验, 甘油三酯, 餐后高血糖, 动脉粥样硬化

LIU Daiyue,LIU Xincan,LAN Zhenzhen. Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches[J]. Chinese General Practice, 2026, 29(18): 2546-2553. DOI: 10.12114/j.issn.1007-9572.2025.0317.
刘岱岳,刘新灿,兰真真. 餐后高脂血症及其治疗的研究进展[J]. 中国全科医学, 2026, 29(18): 2546-2553. DOI: 10.12114/j.issn.1007-9572.2025.0317.

References 67

[1]	国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2024概要[J]. 中国循环杂志, 2025, 40(6): 521-559. DOI: 10.3969/j.issn.1000-3614.2025.06.001.
[2]	PATSCH J R, MIESENBÖCK G, HOPFERWIESER T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state[J]. Arterioscler Thromb, 1992, 12(11): 1336-1345. DOI: 10.1161/01.atv.12.11.1336.
[3]	NIKKILÄ M, SOLAKIVI T, LEHTIMÄKI T, et al. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease[J]. Atherosclerosis, 1994, 106(2): 149-157. DOI: 10.1016/0021-9150(94)90120-1.
[4]	NAKAMURA K, MIYOSHI T, YUNOKI K, et al. Postprandial hyperlipidemia as a potential residual risk factor[J]. J Cardiol, 2016, 67(4): 335-339. DOI: 10.1016/j.jjcc.2015.12.001.
[5]	ALDRED H E, PERRY I C, HARDMAN A E. The effect of a single bout of brisk walking on postprandial lipemia in normolipidemic young adults[J]. Metabolism, 1994, 43(7): 836-841. DOI: 10.1016/0026-0495(94)90263-1.
[6]	MASUDA D, YAMASHITA S. Postprandial hyperlipidemia and remnant lipoproteins[J]. J Atheroscler Thromb, 2017, 24(2): 95-109. DOI: 10.5551/jat.rv16003.
[7]	HAVEL R J. Remnant lipoproteins as therapeutic targets[J]. Curr Opin Lipidol, 2000, 11(6): 615-620. DOI: 10.1097/00041433-200012000-00008.
[8]	ZILVERSMIT D B. Atherogenesis: a postprandial phenomenon[J]. Circulation, 1979, 60(3): 473-485. DOI: 10.1161/01.cir.60.3.473.
[9]	NAKAJIMA K, NAKANO T, TOKITA Y, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons[J]. Clin Chim Acta, 2011, 412(15/16): 1306-1318. DOI: 10.1016/j.cca.2011.04.018.
[10]	NAKAJIMA K, SAITO T, TAMURA A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels[J]. Clin Chim Acta, 1993, 223(1/2): 53-71. DOI: 10.1016/0009-8981(93)90062-9.
[11]	KAHRI J, FRUCHART-NAJIB J, MATIKAINEN N, et al. The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity[J]. Diabetes Care, 2007, 30(8): 2083-2085. DOI: 10.2337/dc07-0100.
[12]	YANAI H, ADACHI H, HAKOSHIMA M, et al. Atherogenic lipoproteins for the statin residual cardiovascular disease risk[J]. Int J Mol Sci, 2022, 23(21): 13499. DOI: 10.3390/ijms232113499.
[13]	KATSIKI N, FILIPPATOS T, VLACHOPOULOS C, et al. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023[J]. Atheroscler Plus, 2024, 55: 74-92. DOI: 10.1016/j.athplu.2024.01.004.
[14]	MASUDA D, NAKAGAWA-TOYAMA Y, NAKATANI K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia[J]. Eur J Clin Invest, 2009, 39(8): 689-698. DOI: 10.1111/j.1365-2362.2009.02163.x.
[15]	NAKAJIMA K, NAKANO T, TOKITA Y, et al. The characteristics of remnant lipoproteins in the fasting and postprandial plasma[J]. Clin Chim Acta, 2012, 413(13/14): 1077-1086. DOI: 10.1016/j.cca.2012.02.026.
[16]	YANAI H, ADACHI H, HAKOSHIMA M, et al. Postprandial hyperlipidemia: its pathophysiology, diagnosis, atherogenesis, and treatments[J]. Int J Mol Sci, 2023, 24(18): 13942. DOI: 10.3390/ijms241813942.
[17]	ISO H, NAITO Y, SATO S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women[J]. Am J Epidemiol, 2001, 153(5): 490-499. DOI: 10.1093/aje/153.5.490.
[18]	EBERLY L E, STAMLER J, NEATON J D, et al. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease[J]. Arch Intern Med, 2003, 163(9): 1077-1083. DOI: 10.1001/archinte.163.9.1077.
[19]	OKAMURA T, TSUKAMOTO K, ARAI H, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022[J]. J Atheroscler Thromb, 2024, 31(6): 641-853. DOI: 10.5551/jat.GL2022.
[20]	MASUDA D, SAKAI N, SUGIMOTO T, et al. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia[J]. J Atheroscler Thromb, 2011, 18(12): 1062-1070. DOI: 10.5551/jat.10470.
[21]	MARCOUX C, TREMBLAY M, NAKAJIMA K, et al. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of typeⅢ and typeⅣ hyperlipoproteinemic patients[J]. J Lipid Res, 1999, 40(4): 636-647.
[22]	YOSHIDA H, KUROSAWA H, HIROWATARI Y, et al. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C)[J]. Lipids Health Dis, 2008, 7: 18. DOI: 10.1186/1476-511X-7-18.
[23]	MIYAUCHI K, KAYAHARA N, ISHIGAMI M, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol[J]. Clin Chem, 2007, 53(12): 2128-2135. DOI: 10.1373/clinchem.2007.092296.
[24]	MAHLEY R W, HUANG Y, RALL S C Jr. Pathogenesis of type Ⅲ hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes[J]. J Lipid Res, 1999, 40(11): 1933-1949.
[25]	GOLDSTEIN J L, SCHROTT H G, HAZZARD W R, et al. Hyperlipidemia in coronary heart disease.Ⅱ. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia[J]. J Clin Invest, 1973, 52(7): 1544-1568. DOI: 10.1172/JCI107332.
[26]	SHOJI T, EMOTO M, KAWAGISHI T, et al. Atherogenic lipoprotein changes in diabetic nephropathy[J]. Atherosclerosis, 2001, 156(2): 425-433. DOI: 10.1016/S0021-9150(00)00673-0.
[27]	林成, 唐志家, 沈茜.糖耐量减低人群TG/HDL-C, TyG及衍生指标与颈动脉粥样硬化关系[J].国际检验医学杂志, 2024, 45(22):2710-2715.
[28]	徐兰梦, 黄榆智, 韩玉竹, 等. 肠道微生物调控脂肪沉积及其代谢相关疾病的研究进展[J]. 畜牧兽医学报, 2024, 55(10):4263-4277. DOI:10.11843/j.issn.0366-6964.2024.10.003.
[29]	AI M, TANAKA A, OGITA K, et al. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes[J]. J Am Coll Cardiol, 2001, 38(6): 1628-1632. DOI: 10.1016/s0735-1097(01)01611-4.
[30]	徐海. 紫苏油对动脉粥样硬化模型动物脂质代谢的干预作用[D]. 重庆: 重庆三峡学院, 2024.
[31]	史菊, 黄小丽, 王宇甜, 等. 小而密低密度脂蛋白胆固醇与冠状动脉病变程度的相关性分析[J]. 中国实用医药, 2024, 19(18): 51-55. DOI: 10.14163/j.cnki.11-5547/r.2024.18.012.
[32]	谭艳美, 陈三俊, 谭玉林, 等. PLIN2在氧化型低密度脂蛋白诱导的泡沫细胞脂噬中的作用[J]. 现代医药卫生, 2023, 39(23): 3966-3969, 3976. DOI: 10.3969/j.issn.1009-5519.2023.23.002.
[33]	O'KEEFE J H, GHEEWALA N M, O'KEEFE J O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health[J]. J Am Coll Cardiol, 2008, 51(3): 249-255. DOI: 10.1016/j.jacc.2007.10.016.
[34]	LEARY M, TANAKA H. Role of fluid milk in attenuating postprandial hyperglycemia and hypertriglyceridemia[J]. Nutrients, 2020, 12(12): 3806. DOI: 10.3390/nu12123806.
[35]	PETRIDOU A, MOUGIOS V. Exercise to lower postprandial lipemia: why, when, what and how[J]. Int J Sports Med, 2022, 43(12): 1013-1022. DOI: 10.1055/a-1810-5118.
[36]	HEALY G N, DUNSTAN D W, SALMON J, et al. Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose[J]. Diabetes Care, 2007, 30(6): 1384-1389. DOI: 10.2337/dc07-0114.
[37]	ROBERTS M J, THACKRAY A E, WADLEY A J, et al. Effect of acute walking on endothelial function and postprandial lipemia in south asians and white Europeans[J]. Med Sci Sports Exerc, 2023, 55(5): 794-802. DOI: 10.1249/MSS.0000000000003098.
[38]	YAMASHITA S, ARAI H, YOKOTE K, et al. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia[J]. J Clin Lipidol, 2018, 12(5): 1267-1279.e4. DOI: 10.1016/j.jacl.2018.06.010.
[39]	CAVALLERO E, DACHET C, ASSADOLAHI F, et al. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control[J]. Atherosclerosis, 2003, 166(1): 151-161. DOI: 10.1016/s0021-9150(02)00321-0.
[40]	JR J G, NGUYEN N H, THEROUX P, et al. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state[J]. J Cardiovasc Pharmacol, 2000, 35(1): 164-172. DOI: 10.1097/00005344-200001000-00022.
[41]	Chinese Medical Association Geriatrics Branch. Expert consensus on the application of ω-3 fatty acid prescription drugs in aging-related diseases (2024 edition)[J]. Zhonghua Yi Xue Za Zhi, 2024, 104(9): 635-649. DOI: 10.3760/cma.j.cn112137-20231018-00809.
[42]	AUSTIN G, FERGUSON J J, THOTA R N, et al. Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids. A randomised cross-over study[J]. Clin Nutr, 2021, 40(2): 420-427. DOI: 10.1016/j.clnu.2020.06.027.
[43]	SPAGNUOLO C M, HEGELE R A. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-Ⅲ inhibitors[J]. Expert Opin Pharmacother, 2023, 24(9): 1013-1020. DOI: 10.1080/14656566.2023.2206015.
[44]	GOUNI-BERTHOLD I, SCHWARZ J, BERTHOLD H K. Updates in drug treatment of severe hypertriglyceridemia[J]. Curr Atheroscler Rep, 2023, 25(10): 701-709. DOI: 10.1007/s11883-023-01140-z.
[45]	GOUNI-BERTHOLD I, ALEXANDER V J, YANG Q Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Diabetes Endocrinol, 2021, 9(5): 264-275. DOI: 10.1016/S2213-8587(21)00046-2.
[46]	HEGELE R A. Apolipoprotein C-Ⅲ inhibition to lower triglycerides: one ring to rule them all?[J]. Eur Heart J, 2022, 43(14): 1413-1415. DOI: 10.1093/eurheartj/ehab890.
[47]	TARDIF J C, KARWATOWSKA-PROKOPCZUK E, AMOUR E S, et al. Apolipoprotein C-Ⅲ reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk[J]. Eur Heart J, 2022, 43(14): 1401-1412. DOI: 10.1093/eurheartj/ehab820.
[48]	CLIFTON P, SULLIVAN D, BAKER J, et al. Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia[J]. Circulation, 2021, 144(Suppl_1): A10357-A. DOI: 10.1161/circ.144.suppl_1.10357
[49]	BALLANTYNE C M, VASAS S, AZIZAD M, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia[J]. N Engl J Med, 2024, 391(10): 899-912. DOI: 10.1056/NEJMoa2404143.
[50]	RAY K K, WRIGHT R S, KALLEND D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16): 1507-1519. DOI: 10.1056/NEJMoa1912387.
[51]	FITZGERALD K, WHITE S, BORODOVSKY A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51. DOI: 10.1056/NEJMoa1609243.
[52]	PADAM P, BARTON L, WILSON S, et al. Lipid lowering with inclisiran: a real-world single-centre experience[J]. Open Heart, 2022, 9(2): e002184. DOI: 10.1136/openhrt-2022-002184.
[53]	黎华, 黎静, 杨云飞, 等. 他汀类药物作用机制及临床应用进展[J]. 中国老年保健医学, 2023, 21(6): 116-119. DOI: 10.3969/j.issn.1672-2671.2023.06.024.
[54]	BYRNE P, DEMASI M, JONES M, et al. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis[J]. JAMA Intern Med, 2022, 182(5): 474-481. DOI: 10.1001/jamainternmed.2022.0134.
[55]	ALVAREZ-JIMENEZ L, MORENO-CABAÑAS A, RAMIREZ-JIMENEZ M, et al. Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: a systematic review and network meta-analysis[J]. J Sport Health Sci, 2022, 11(5): 567-577. DOI: 10.1016/j.jshs.2021.07.006.
[56]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255. DOI: 10.3760/cma.j.cn112148-20230119-00038.
[57]	NAKAMURA A, SATO K, KANAZAWA M, et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease[J]. Heart Vessels, 2019, 34(6): 916-925. DOI: 10.1007/s00380-018-1319-x.
[58]	HAN Y L, CHEN J Y, CHOPRA V K, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand[J]. J Clin Lipidol, 2020, 14(1): 98-108.e8. DOI: 10.1016/j.jacl.2019.10.015.
[59]	WEINTRAUB M S, CHARACH G, GROSSKOPF I. Effects of fibric acid derivatives and metformin on postprandial lipemia[J]. Atherosclerosis, 1998, 141(Suppl 1): S71-S75. DOI: 10.1016/s0021-9150(98)00221-4.
[60]	KADO S, MURAKAMI T, AOKI A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 1998, 41(1): 49-55. DOI: 10.1016/S0168-8227(98)00062-X.
[61]	ABBASI F, LAMENDOLA C, LEARY E T, et al. Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers[J]. Diabetes Obes Metab, 2009, 11(8): 779-785. DOI: 10.1111/j.1463-1326.2009.01041.x.
[62]	NOVODVORSKÝ P, HALUZÍK M. The effect of GLP-1 receptor agonists on postprandial lipaemia[J]. Curr Atheroscler Rep, 2022, 24(1): 13-21. DOI: 10.1007/s11883-022-00982-3.
[63]	TASKINEN M R, BJÖRNSON E, MATIKAINEN N, et al. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(5): 1191-1201. DOI: 10.1111/dom.14328.
[64]	BUNCK M C, CORNÉR A, ELIASSON B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress[J]. Atherosclerosis, 2010, 212(1): 223-229. DOI: 10.1016/j.atherosclerosis.2010.04.024.
[65]	WANG S J, REN H H, ZHONG H Z, et al. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study[J]. Gut Microbes, 2022, 14(1): 2003176. DOI: 10.1080/19490976.2021.2003176.
[66]	MORROW N M, TRZASKALSKI N A, HANSON A A, et al. Nobiletin prevents high-fat diet-induced dysregulation of intestinal lipid metabolism and attenuates postprandial lipemia[J]. Arterioscler Thromb Vasc Biol, 2022, 42(2): 127-144. DOI: 10.1161/ATVBAHA.121.316896.
[67]	XU D Y, SHU J, HUANG Q Y, et al. Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine[J]. Atherosclerosis, 2010, 211(1): 237-241. DOI: 10.1016/j.atherosclerosis.2010.01.044.